Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- AZ, SCC to Help Elimination of Drug Lag through Joint Research
September 1, 2008
- Prasugrel Inhibits Recurrence of CV Events More Effectively than Clopidogrel
September 1, 2008
- REGULATORY NEWS IN BRIEF
September 1, 2008
- MCHC Aims at Developing Comprehensive Healthcare Businesses: President Kobayashi
September 1, 2008
- Largest Number of Drugs Unavailable in Japan among 11 Countries: OPIR Survey
September 1, 2008
- Depression Linked to Changes in Cerebral Blood Flow
September 1, 2008
- Criteria for Use of Thalidomide Announced
September 1, 2008
- Wholesalers' SGA Expense Ratio Drops to below 7% for the First Time
August 25, 2008
- Eliminating Losses due to Invoice Prices Higher than Sales Prices Is Not Easy: Mr Matsutani
August 25, 2008
- SSP Aims at Growth Rate 2 Points Above Industry Average: President Hatori
August 25, 2008
- Price Settlement Rate Reaches 53% as of July 31: Mediceo Paltac
August 25, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 25, 2008
- Price Settlement Rates as of End of June Similar to Those Reported 2 Years Ago
August 25, 2008
- 13th ACCJ Media Lectures
August 25, 2008
- Bayer, FUJIFILM RI Pharma Start Receiving Orders on Zevalin
August 25, 2008
- Market Price Surveys to Focus on Generics
August 25, 2008
- Pfizer Starts Detailing Macugen for AMD
August 25, 2008
- R&D NEWS IN BRIEF
August 25, 2008
- Top Management Changes Made within 2 Months Announced by Ono
August 25, 2008
- Development of New Drugs for AMD Stimulated
August 25, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…